280 related articles for article (PubMed ID: 16291708)
1. Clinical trials in amyotrophic lateral sclerosis: the tenuous past and the promising future.
Choudry RB; Cudkowicz ME
J Clin Pharmacol; 2005 Dec; 45(12):1334-44. PubMed ID: 16291708
[TBL] [Abstract][Full Text] [Related]
2. Drug therapy in amyotrophic lateral sclerosis.
Murray B; Mitsumoto H
Adv Neurol; 2002; 88():63-82. PubMed ID: 11908237
[No Abstract] [Full Text] [Related]
3. Drug therapy for amyotrophic lateral sclerosis: Where are we now?
Carter GT; Krivickas LS; Weydt P; Weiss MD; Miller RG
IDrugs; 2003 Feb; 6(2):147-53. PubMed ID: 12789618
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials in ALS: an overview.
Turner MR; Parton MJ; Leigh PN
Semin Neurol; 2001 Jun; 21(2):167-75. PubMed ID: 11442325
[TBL] [Abstract][Full Text] [Related]
5. [Riluzole treatment in amyotrophic lateral sclerosis].
Wokke JH
Ned Tijdschr Geneeskd; 1996 Nov; 140(46):2265-8. PubMed ID: 8984377
[No Abstract] [Full Text] [Related]
6. [Neurotrophins. II: therapeutic potential].
Zazpe A; Del Río J
Rev Med Univ Navarra; 1997; 41(3):180-4. PubMed ID: 10420924
[TBL] [Abstract][Full Text] [Related]
7. Riluzole for amyotrophic lateral sclerosis.
Med Lett Drugs Ther; 1995 Dec; 37(963):113-4. PubMed ID: 7500908
[No Abstract] [Full Text] [Related]
8. Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy.
Weiss MD; Weydt P; Carter GT
Expert Opin Pharmacother; 2004 Apr; 5(4):735-46. PubMed ID: 15102560
[TBL] [Abstract][Full Text] [Related]
9. Intrathecal delivery of hepatocyte growth factor from amyotrophic lateral sclerosis onset suppresses disease progression in rat amyotrophic lateral sclerosis model.
Ishigaki A; Aoki M; Nagai M; Warita H; Kato S; Kato M; Nakamura T; Funakoshi H; Itoyama Y
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1037-44. PubMed ID: 17984685
[TBL] [Abstract][Full Text] [Related]
10. [Glutamate antagonist].
Shindo M
No To Shinkei; 1998 Jul; 50(7):597-605. PubMed ID: 9739517
[No Abstract] [Full Text] [Related]
11. Therapeutic advances in amyotrophic lateral sclerosis.
Louvel E; Hugon J; Doble A
Trends Pharmacol Sci; 1997 Jun; 18(6):196-203. PubMed ID: 9226998
[TBL] [Abstract][Full Text] [Related]
12. Clinical development of levetiracetam for amyotrophic lateral sclerosis.
Davies SL; Moral MA
Drug News Perspect; 2006 Nov; 19(9):572-3. PubMed ID: 17220961
[TBL] [Abstract][Full Text] [Related]
13. Selecting promising ALS therapies in clinical trials.
Glass JD; Benatar M; Polak M
Neurology; 2007 May; 68(18):1545-6; author reply 1546. PubMed ID: 17470765
[No Abstract] [Full Text] [Related]
14. Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls.
Henderson CE
Adv Neurol; 1995; 68():235-40. PubMed ID: 8787235
[No Abstract] [Full Text] [Related]
15. Designing clinical trials in amyotrophic lateral sclerosis.
Shefner JM
Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
[TBL] [Abstract][Full Text] [Related]
16. A placebo arm is not always necessary in clinical trials of amyotrophic lateral sclerosis.
Gordon PH
Muscle Nerve; 2009 Jun; 39(6):858-60. PubMed ID: 19382169
[TBL] [Abstract][Full Text] [Related]
17. Lay-offs follow suspension of clinical trials of protein.
Verrall M
Nature; 1994 Jul; 370(6484):6. PubMed ID: 8015607
[No Abstract] [Full Text] [Related]
18. Recent advances in the therapy of amyotrophic lateral sclerosis: focus on excitotoxicity.
Brighina L; Sala G; Ceresa C; Tremolizzo L; Ferrarese C
Funct Neurol; 2001; 16(4 Suppl):189-202. PubMed ID: 11996516
[No Abstract] [Full Text] [Related]
19. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
Malta E
Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
[TBL] [Abstract][Full Text] [Related]
20. [ALS and neurotrophic factors--HGF as a novel neurotrophic and neuroregenerative factor].
Funakoshi H; Ohya W; Kadoyama K; Nakamura T
Brain Nerve; 2007 Oct; 59(10):1195-202. PubMed ID: 17969361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
